# Next-generation phenotypic antimicrobial susceptibility test platform: rapid resultsand comprehensive menus

> **NIH NIH SB1** · SELUX DIAGNOSTICS, INC. · 2021 · $999,992

## Abstract

The goal of this CRP SBIR proposal is to fund four projects to advance the commercial
readiness of Selux’s rapid, comprehensive, low-cost, phenotypic antibiotic susceptibility
test (AST) system. Selux’s next-generation phenotyping (NGP) platform uniquely enables rapid
AST with comprehensive antimicrobial menus of >50 drugs at a low cost from isolates and
positive blood culture samples. Aims 1 and 2 focus on cost reduction projects important for early
customer adoption. Aim 1 comprises analytical studies to support multiplex oral panels and Aim
2 is a DFM redesign of the Analyzer consumable pack. Aims 3 and 4 focuses on work
necessary for later customer adoption. Aim 3 is a yearlong benchmarking study that will
compare Selux NGP performance against legacy AST systems and reference methods. By
improving system workflows and benchmarking AST performance across legacy systems CRP
funding will help position Selux NGP as the dominant AST platform of the future.

## Key facts

- **NIH application ID:** 10325484
- **Project number:** 2SB1AI136125-04A1
- **Recipient organization:** SELUX DIAGNOSTICS, INC.
- **Principal Investigator:** ERIC STERN
- **Activity code:** SB1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $999,992
- **Award type:** 2
- **Project period:** 2018-01-01 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10325484

## Citation

> US National Institutes of Health, RePORTER application 10325484, Next-generation phenotypic antimicrobial susceptibility test platform: rapid resultsand comprehensive menus (2SB1AI136125-04A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10325484. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*